Results 201 to 210 of about 13,157 (218)

Long-acting muscarinic M₃receptor antagonists

Expert Opinion on Therapeutic Patents, 2006
Two applications claim a novel class of muscarinic M3 receptor antagonists and their use as long-acting agents for the treatment of chronic obstructive pulmonary disease.
openaire   +1 more source

Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β2-Agonist Plus Inhaled Long-Acting Muscarinic Antagonist vs Inhaled Long-Acting β2-Agonist Plus Inhaled Corticosteroid Fixed-Dose Combinations in COPD A Propensity Score-Inverse Probability of Treatment Weighting Cohort Study

Chest, 2021
Meng-Ting Wang, Jun-Ting Liou, Yu-Juei Hsu   +2 more
exaly  

The efficacy and safety of additional treatment with short-acting muscarinic antagonist combined with long-acting beta-2 agonist in stable patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis

Chronic Respiratory Disease, 2023
Kazuya Tanimura, Susumu Sato, Yukio Fujita   +2 more
exaly  

Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD.

Current opinion in investigational drugs (London, England : 2000), 2009
Aclidinium bromide is a novel, inhaled, long-acting antimuscarinic agent being developed by Almirall Prodesfarma SA and Forest Laboratories Inc as a once-daily treatment for COPD. In preclinical studies, aclidinium bromide demonstrated a comparable profile to tiotropium bromide, with a slightly quicker onset of action but shorter duration of action ...
openaire   +2 more sources

Clinical Efficacy of Long-Acting β2 Agonists and Long-Acting Muscarinic Antagonist for Moderate to Severe Chronic Obstructive Pulmonary Disease

Pharmaceutical Chemistry Journal, 2023
Yongqian Xu, Yu Pang, Xu Yongqian
exaly  

Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients

Respiratory Medicine, 2010
Y Fukuchi, T Overend, N Prasad
exaly  

Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combinations in COPD

Therapeutic Advances in Respiratory Disease, 2019
Martin Jenkins, Mario Ouwens, Patrick Darken   +2 more
exaly  

The Effect of Long-acting Muscarinic Antagonist on Airway Inflammation Through Leukotrienes

A31. GLOBAL AND ENVIRONMENTAL INFLUENCES IN ASTHMA, 2023
T. Matsuyama, K. Machida, H. Matsuyama, Y. Dotake, K. Takagi, H. Inoue   +5 more
openaire   +1 more source

Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies

Pulmonary Pharmacology and Therapeutics, 2018
David L Bourdet, Brett Haumann, Dave Singh   +2 more
exaly  

Aclidinium bromide, a novel long-acting muscarinic antagonist for COPD with improved preclinical renal and urinary safety profile

Life Sciences, 2012
Amadeu Gavalda, Jorge Beleta, Jesus Llenas   +2 more
exaly